Absolute neutrophil count (ANC) >= /mm^, independent of growth factor support, documented within  days of registration
Absolute neutrophil count (ANC) > , cells/dL (. x e/L) (growth factor cannot be used within the previous  days)
Absolute neutrophil count >= . x ^/L within  days of treatment initiation and must be independent of hematopoietic growth factor support
Absolute neutrophil count ?,/mm without growth factor use ?  days prior to treatment (cycle  day , CD)
Absolute neutrophil count (ANC) >= /uL (with/without growth factor)
Absolute neutrophil count (ANC) >= . x ^/L without growth factor support, at the screening visit
Absolute neutrophil count (ANC) >= . x ^/L without growth factor support
Absolute neutrophil count (ANC): >= /mm^, must be at least days after last dose of growth factor
Absolute neutrophil count >= ,/mcL without growth factor support, =<  days prior to CD
Absolute neutrophil count > /mm^ without the support of growth factors
Absolute neutrophil count (ANC) >= , cell/mm^ without growth factor support, obtained =<  days prior to registration
Absolute neutrophil count (ANC) ? /uL, with or without chronic granulocyte growth factor support
STRATUM A: Absolute neutrophil count (ANC) >= /mm^ without growth factor support within  days of the test
Absolute neutrophil count (ANC) >= /mm^ independent of growth factor support
Absolute neutrophil count ? /mcL, and have not received any growth factor support for at least  weeks prior to screening
To be performed within  days prior to day  of protocol therapy: Absolute neutrophil count (ANC) >= ,/mm^\r\n* NOTE: growth factor support is not permitted to normalize baseline ANC parameters, however subsequent growth factor administration is permitted as standard supportive care
Absolute neutrophil count (ANC) > ,/mm^ independent of growth factor support
Absolute neutrophil counts of >= /uL (without growth factor support) results within  days before study drug administration
Absolute neutrophil count (ANC) >= . x ^/L in absence of growth factor support
Absolute neutrophil count (ANC) >= /ul in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by >= % CLL in marrow
Absolute neutrophil count (ANC) < ,/mm without growth factor support within  days prior to testing
Participants with an absolute neutrophil count (ANC) >= /mm^, within  days of initiation of protocol therapy; growth factor within  days of screening is not allowed to meet ANC eligibility criteria
Participants with an absolute neutrophil count (ANC) < /mm^, within  days of initiation of protocol therapy; growth factor within  days of screening is not allowed to meet ANC eligibility criteria
Absolute neutrophil count (ANC) >= ,/mm^ without transfusion or growth factor support for at least  week
Absolute neutrophil >= ,/mcL; transfusion and/or growth factor are permitted within any timeframe
Obtained =<  days prior to registration: Absolute neutrophil count (ANC) >= , cell/mm^ without growth factor support
Within  days prior to planned start of treatment: Absolute neutrophil count (ANC) >= /mm^\r\n* Growth factor is not permitted within  days of ANC assessment unless cytopenia is secondary to disease involvement
Absolute neutrophil count >= ,/mcL (without growth factor support)
Absolute neutrophil count >= /mcL (in the absence of growth factor support), within  days prior to treatment
Absolute neutrophil count (ANC) >= /mm^ independent of growth factor support
Absolute neutrophil count >= ,/mcL, regardless of transfusion or growth factor support
Absolute neutrophil count (ANC) ? . K/mm^ (must be stable off any growth factor within  weeks of first study drug administration)
Absolute neutrophil count (ANC) >= . x ^/L without daily use of myeloid growth factor
PART  GROUP  INCLUSION CRITERIA: Peripheral absolute neutrophil count (ANC) >= /mm^ (. x ^/L) without granulocyte growth factor for >=  days
PHASE I: Absolute neutrophil count >= ,/mcL without growth factor support
PHASE II SCLC: Absolute neutrophil count >= ,/mcL without growth factor support
UROTHELIAL CARCINOMA EXPANSION COHORT: Absolute neutrophil count >= ,/mcL without growth factor support
mCRPC EXPANSION COHORT: Absolute neutrophil count >= ,/mcL without growth factor support
Absolute neutrophil count >=  cells/mm^, with or without transfusion support; NOTE: If the patients bone marrow biopsy shows greater than or equal to % plasma cells, absolute neutrophil count (ANC) >  cells/mm^ (transfusion support or growth factor support is acceptable)
Absolute neutrophil count (ANC) >= ,/mcL with no growth factor support in the previous  weeks
Absolute neutrophil count (ANC) >= , cells/ul without growth factor support
Absolute neutrophil count >= ,/mm^ without growth factor use =<  days prior to CD
Absolute neutrophil count (ANC) >= /mm^; growth factor is not permitted within  days of neutrophil assessment
Absolute neutrophil count (ANC) >= /mm^ or >= /mm^ in the setting of marrow involvement by disease (independent of growth factor or transfusion support)
Absolute neutrophil count (ANC) ? /mm, independent of growth factor support;
Absolute neutrophil count (ANC) /cu mm (off myeloid growth factors)
Absolute neutrophil count (ANC) >= ,/mm^ without growth factor support
Absolute neutrophil count >= . x ^ cells/L (growth factor use is allowed)
Absolute neutrophil count >= ,/mcL (without growth factor support)
Absolute neutrophil count >= . K/mcL, without use of growth factor support for  week
Obtained =<  days prior to registration: Absolute neutrophil count (ANC) >= /uL (without growth factor support)
Absolute neutrophil count (ANC) >= . x ^/L; screening ANC should be independent of growth factor support for over one week for all patients
Received growth factor support or transfusions to achieve hematology entry criteria (platelets, hemoglobin, absolute neutrophil count)
Absolute neutrophil count (ANC) >/= , cells/ul without growth factor support prior to initial treatment
Within  days prior to day  of protocol therapy unless otherwise stated: Absolute neutrophil count (ANC) >= ,/mm^\r\n* NOTE: Growth factor is not permitted within  days of ANC assessment unless cytopenia is secondary to disease involvement
Absolute neutrophil count (ANC) >= ,/mm^ (without transfusion or growth factor support)
To be performed within  days prior to day  of protocol therapy: Absolute neutrophil count (ANC) >= /mm^\r\n* NOTE: Growth factor is not permitted within  days of ANC assessment unless cytopenia is secondary to disease involvement
Obtained within  days (or as stipulated) prior to study drug (treatment) administration: absolute neutrophil count (ANC) ?  cells/ul (growth factor cannot be used within the previous  days)
Absolute neutrophil count (ANC) >= . x ^/L without growth factor support
Absolute neutrophil count (ANC) >= , cell/mm^ without growth factor support within  days prior to registration
Participants with an absolute neutrophil count (ANC) < /mm^, within  days of initiation of protocol therapy; growth factor within  days of screening is not allowed to meet ANC eligibility criteria
Evidence of myeloid engraftment (eg, absolute neutrophil count ? .  ^/L for  consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed.
Absolute neutrophil count (ANC) < , cells/mm^ within  days of initiation of protocol therapy; growth factor administration is not allowed to meet ANC eligibility criteria
Absolute neutrophil count (ANC) >= /ul (without growth factor support)
Within  days prior to randomization: Absolute neutrophil count (ANC) >=  cells/mcL (. x ^/L); hence ANC must be >= /mcL without myeloid growth factor support
Absolute neutrophil count (ANC) ? . x ^/uL without treatment with a myeloid growth factor within  days prior to first dose of IP
Absolute neutrophil count (ANC) >= . x ^/L without growth factor support
Within  days prior to registration: Absolute neutrophil count (ANC) >= , cells/mm^ without growth factor support
Absolute Neutrophil Count (ANC) ? . x /L without growth factor support for  days ( days if received pegfilgrastim).
Absolute neutrophil count (ANC) ? . x ^/L in the absence of growth factor in the prior  days
Within  h of initiating study treatment: Absolute neutrophil count (ANC) >= /mm^; Note: transfusions of blood and blood products as well as growth factor support are prohibited within  days prior to the first dose of study treatment
Absolute neutrophil count (ANC) >= . x ^ /L, independent of growth factor support unless with bone marrow involvement for  days
Within  days prior to signing informed consent: Absolute neutrophil count (ANC) >= ,/mm^, independent of growth factor support
Absolute neutrophil count >= ,/mcL without growth-factor support during the past month
Absolute neutrophil count (ANC) ? /mm (screening ANC should be independent of growth factor support for ?  week)
Participants with an absolute neutrophil count (ANC) <  cells/mm^ at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within  days of obtaining screening evaluation
Absolute neutrophil count >= . x ^ cells/L (growth factor use is allowed)
Absolute neutrophil count (ANC) > . x ^/L in the absence of growth factor in the prior  days
At least  weeks ( days) prior to registration: Absolute neutrophil count (ANC) >= . x ^/L without growth factor support
Absolute neutrophil count (ANC) >= .  ^/L (without transfusion support and without hematological growth factor support within  weeks of cycle  day )
Participants with an absolute neutrophil count (ANC) <  cells/mm^ at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within  days of obtaining screening evaluation
Absolute neutrophil count (ANC) >= . x ^ /L. No transfusion or growth factor support for one week prior to labs.
Absolute neutrophil count >= ,/mcL in the absence of growth factor administration
Absolute neutrophil count (ANC) >= /ul (without growth factor support)
Neutrophils < . x ^/L (neutrophil count should be >  without growth factor support, unless neutropenia is caused by anti-neutrophil antibodies or other manifestation of chronic GVHD)
Absolute neutrophil count (ANC) > , (growth factors permitted)
Absolute neutrophil count (ANC) >= . x ^/L (growth factors not permitted to make eligible)
Absolute neutrophil count (ANC) equal or greater to  without growth factor support for at least  days
Absolute neutrophil count (ANC) >= , cells/mm^ (without platelet transfusion or myeloid growth factor support within two weeks of screening)
Absolute neutrophil count (ANC) >=  cells/mm without growth factor support
Absolute neutrophil count >= ,/mcL*\r\n* Participants may be receiving growth factor support to meet these criteria
Absolute neutrophil count >= . K/uL (growth factor support is permissible)
Peripheral absolute neutrophil count (ANC) >= /mm^; \r\n* Note: must be >  days from use of hematopoietic growth factor or  days from pegfilgastrim
Absolute neutrophil count (ANC) < ,/mm without growth factor support within  days prior to testing
Absolute neutrophil count >=, per cubic millimeter (/mm^), not supported by growth factor
Absolute Neutrophil count (ANC) ? . x /L without daily use of myeloid growth factor; and
Absolute neutrophil count (ANC) >= /mm^ (. x ^/L) (participants receiving transfusion, erythropoietin, or myeloid growth factor support will be eligible for this study)
Absolute neutrophil count (ANC) ? /mm within  days prior to randomization. Screening ANC should be independent of growth factor support for ?  week.
Absolute neutrophil count (ANC) >= , cells/dL (. x ^/L) (growth factors cannot be used within  days of first drug administration)
Absolute neutrophil count >= ,/mcL independent of growth factor support
Absolute neutrophil count >= . x ^/L (without growth factor support)
Absolute neutrophil count (ANC) >= . x ^/L (growth factor support is allowed to reach this goal)
Absolute neutrophil count (ANC) >= . x ^/L without growth factor support
Absolute neutrophil count >=  cells/mm^ (. x ^/L); growth factor allowed to achieve
Absolute neutrophil count (ANC) >= /ul without growth factor or transfusional support
Absolute neutrophil count (ANC) >= /ul without growth factor or transfusional support
Subjects must have the following laboratory values: Absolute Neutrophil Count (ANC) ? . x /L without growth factor support for  days ( days if subject received pegfilgrastim).
Absolute neutrophil count (ANC) >= . X ^/L without (w/o) myeloid growth factor support for  days preceding lab assessment, obtained within  days prior to PET scan
Absolute neutrophil count (ANC) ?. x /L (in absence of growth factor support)